A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer
Public ClinicalTrials.gov record NCT01120561. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Expanded Access, Open-Label Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer
Study identification
- NCT ID
- NCT01120561
- Recruitment status
- No Longer Available
- Study type
- Expanded access
- Phase
- Not listed
- Lead sponsor
- Genentech, Inc.
- Industry
- Enrollment
- Not listed
Conditions and interventions
Conditions
Interventions
- trastuzumab-MCC-DM1 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2010
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Feb 14, 2017
Started 2010
United States locations
- U.S. sites
- 15
- U.S. states
- 14
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site | Highland | California | 92346 | — |
| Investigational Site | Stockton | California | 95204 | — |
| Investigational Site | Denver | Colorado | 80220 | — |
| Investigational Site | Plantation | Florida | 33324 | — |
| Investigational Site | Lafayette | Indiana | 47905 | — |
| Investigational Site | Cedar Rapids | Iowa | 52403 | — |
| Investigational Site | Scarborough | Maine | 04074 | — |
| Investigational Site | Baltimore | Maryland | 21231 | — |
| Investigational Site | Detroit | Michigan | 48201 | — |
| Investigational Site | Clarkson Valley | Missouri | 63011 | — |
| Investigational Site | Farmington | New Mexico | 87401 | — |
| Investigational Site | Charlotte | North Carolina | 28203 | — |
| Investigational Site | Charleston | South Carolina | 29403 | — |
| Investigational Site | Fairfax | Virginia | 22031 | — |
| Investigational Site | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01120561, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 14, 2017 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01120561 live on ClinicalTrials.gov.